Journal for Immunotherapy of Cancer

Papers
(The TQCC of Journal for Immunotherapy of Cancer is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death523
TIGIT in cancer immunotherapy356
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB H300
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events274
LAG-3: from molecular functions to clinical applications240
Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future231
Tim-3 finds its place in the cancer immunotherapy landscape212
Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity197
Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer185
Clinical landscape of oncolytic virus research in 2020181
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances155
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinica146
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events129
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial126
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometri121
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial121
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice119
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation118
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce115
ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma115
Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?115
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition113
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy112
ARID1Aalterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy108
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing103
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation97
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma95
Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review93
Interferon gamma inhibits CXCL8–CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer93
Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation93
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma93
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer92
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer92
Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes92
Acute kidney injury in patients treated with immune checkpoint inhibitors91
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies91
M1hottumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer90
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer88
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy88
TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma87
Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer87
Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers86
IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma86
Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma85
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer85
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer84
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial84
Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker84
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead83
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study81
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial80
CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer79
Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma79
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer79
Phase 2 study of pembrolizumab in patients with advanced rare cancers78
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial77
On the mechanism of anti-CD39 immune checkpoint therapy77
Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib77
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma77
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers76
Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy76
Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy75
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone75
Therapeutic depletion of CCR8+tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy75
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial74
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemothera74
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up74
Intratumoral TIGIT+ CD8+ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer74
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations73
Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L172
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors72
Rethinking immune checkpoint blockade: ‘Beyond the T cell’72
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma72
Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer71
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors71
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies69
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy69
Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC69
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies68
Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial68
Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma67
Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery67
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA67
Severity of COVID-19 in patients with lung cancer: evidence and challenges67
Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer67
T-cell agonists in cancer immunotherapy67
Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images67
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies67
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study67
Mitochondrial Lon-induced mtDNA leakage contributes to PD-L1–mediated immunoescape via STING-IFN signaling and extracellular vesicles67
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response66
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade65
LAG3(LAG-3,CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma65
Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL1065
TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer65
Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity65
Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study64
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma64
Deregulation of HLA-I in cancer and its central importance for immunotherapy64
CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy64
Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer64
Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity63
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma63
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma63
Correction: Consensus guidelines for the definition, detection and interpretation of immunogenic cell death62
Considerations for treatment duration in responders to immune checkpoint inhibitors62
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors62
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade61
Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival61
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study61
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy61
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)61
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy61
Antigen processing and presentation in cancer immunotherapy60
Tumors establish resistance to immunotherapy by regulating Tregrecruitment via CCR460
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma60
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors60
Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy59
EpCAM-high liver cancer stem cells resist natural killer cell–mediated cytotoxicity by upregulating CEACAM159
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer59
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages58
S100A4 enhances protumor macrophage polarization by control of PPAR-γ-dependent induction of fatty acid oxidation57
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer57
Evolving impact of long-term survival results on metastatic melanoma treatment57
Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade57
Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy57
Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis56
LRP1Bmutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types56
Strategies for improving the management of immune-related adverse events55
IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma55
Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck55
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial55
Lung metastases share common immune features regardless of primary tumor origin55
Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance55
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors55
STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment55
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma54
Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy54
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma53
Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer53
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation53
Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma53
CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency53
Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.53
Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response53
Cellular cytotoxicity is a form of immunogenic cell death53
M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer53
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity52
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors52
Immunogenic ferroptosis and where to find it?52
Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma52
Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer52
CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer51
Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions51
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer51
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)51
Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+conventional dendritic cells50
Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies50
Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia50
Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma50
Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy50
Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas50
Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity50
Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer49
Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study49
Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy49
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma49
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma49
Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma49
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial49
Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma49
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients49
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD849
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial49
Lifting the innate immune barriers to antitumor immunity48
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program48
TFEB is a master regulator of tumor-associated macrophages in breast cancer48
Immunotherapy for sarcomas: new frontiers and unveiled opportunities48
Chronic immune checkpoint inhibitor pneumonitis48
Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma48
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis48
A signature for pan-cancer prognosis based on neutrophil extracellular traps48
CD200 promotes immunosuppression in the pancreatic tumor microenvironment48
C reactive protein impairs adaptive immunity in immune cells of patients with melanoma47
Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities47
Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity46
Neutrophils in the era of immune checkpoint blockade46
Point mutation inCD19facilitates immune escape of B cell lymphoma from CAR-T cell therapy46
On the use of immune checkpoint inhibitors in patients with viral infections including COVID-1946
Deletion of Cbl-b inhibits CD8+ T-cell exhaustion and promotes CAR T-cell function46
High-dimensional immune-profiling in cancer: implications for immunotherapy45
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-1945
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer45
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL45
STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer45
Exercise and the immune system: taking steps to improve responses to cancer immunotherapy44
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy44
Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines44
Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response44
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study44
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis44
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study44
Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis44
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer44
Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma43
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma43
Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer43
COVID-19 and immune checkpoint inhibitors: initial considerations43
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial43
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine43
Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study43
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)43
Overcoming hypoxia-induced functional suppression of NK cells42
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemothe42
Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells42
Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT342
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma42
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers42
Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer42
Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes42
Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses42
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort42
Aged neutrophils form mitochondria-dependent vital NETs to promote breast cancer lung metastasis42
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma42
Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma41
GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma41
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study41
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes41
MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer41
Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer41
Interleukin-15 and cancer: some solved and many unsolved questions41
Cell death induced by cytotoxic CD8+T cells is immunogenic and primes caspase-3–dependent spread immunity against endogenous tumor antigens41
Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherap41
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies41
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy41
Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma40
m6A modification patterns and tumor immune landscape in clear cell renal carcinoma40
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition40
Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy40
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy40
Characterization of human cancer xenografts in humanized mice40
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer40
Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors40
Role of Fcγ receptors in HER2-targeted breast cancer therapy40
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma40
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes40
Obesity diminishes response to PD-1-based immunotherapies in renal cancer40
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma39
Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity39
RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL 39
0.037063121795654